A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Recruiting · NCT06064890 · Registry updated 2026-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) | Frontotemporal Lobar Degeneration, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, aphasia, brain disorder, central nervous system disorder, cognitive disorder, communication disorder, dementia, frontotemporal dementia, language disorder, metabolic disease, nervous system disorder, neurodegenerative disease, primary progressive aphasia, proteostasis deficiencies, psychiatric disorder, speech disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-13 | NCT06064890 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AviadoBio Ltd | 1 |
19 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.